Cero Therapeutics Holdings, Inc. (CERO) Stock Price & Analysis
Cero Therapeutics Holdings, Inc. (CERO) rose 1.44% to USD 0.01 as of June 10, 2026 at 02:30 UTC, according to Nexqual real-time market data.
CERO last closed at USD 0.01; the session ranged USD 0.01–0.01 on volume of 818,282 shares. Market capitalization is $478,191, with a 52-week range of USD 0.01–26.99 (OQB). Source: Nexqual, June 10, 2026 at 02:30 UTC.
Key Statistics (as of June 10, 2026 at 02:30 UTC)
| Price | USD 0.01 |
|---|---|
| Change | ▲ 1.44% (up) |
| Previous Close | USD 0.01 |
| Open | USD 0.01 |
| Day Range | USD 0.01 – 0.01 |
| 52-Week Range | USD 0.01 – 26.99 |
| Volume | 818,282 shares |
| Market Cap | $478,191 |
| Exchange | OQB |
Technical Analysis (CERO)
Nexqual's technical model rates CERO "SELL" based on 2 bullish and 5 bearish signals across 124 daily candles, as of June 10, 2026 at 02:30 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 29.27 (oversold) |
| vs SMA50 | Below (USD 0.03) |
| MACD | -0 (negative) |
Analyst Ratings (CERO)
Wall Street analysts rate CERO "None", per Nexqual as of June 10, 2026 at 02:30 UTC.
| Consensus Rating | None |
|---|---|
| Buy / Hold / Sell | 0 / 1 / 0 |
Earnings (CERO)
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2025-09-30 | USD -9.1 vs est -4.35 ▼ miss |
| 2025-06-30 | USD -61.71 vs est -6.21 ▼ miss |
| 2025-03-31 | USD -31.8 vs est -119.2 ▲ beat |
Source: Nexqual, June 10, 2026 at 02:30 UTC.
Financials & Fundamentals (CERO)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| Current Ratio | 0.14 |
| Total Cash | $857,489 |
| Total Debt | $598,345 |
| Free Cash Flow | $-5.14M |
Source: Nexqual, June 10, 2026 at 02:30 UTC.
Financial Health Score (CERO)
Nexqual rates Cero Therapeutics Holdings, Inc.'s overall financial health "Weak" across five dimensions, as of June 10, 2026 at 02:30 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Mixed — $857K cash, no debt |
| Cash Flow | Weak — Operating cash flow -$14M |
| Efficiency | Mixed — No data |
Ownership (CERO)
| Insider Ownership | +4.13% |
|---|---|
| Institutional Ownership | +0.14% |
| Shares Outstanding | 45.11M |
| Float | 43.14M |
| Short % of Float | +10.50% |
Source: Nexqual, June 10, 2026 at 02:30 UTC.
Leadership (CERO)
Cero Therapeutics Holdings, Inc. is led by Christopher B. Ehrlich (age 55), CEO & Chair, per Nexqual as of June 10, 2026 at 02:30 UTC.
| CEO & Chair | Christopher B. Ehrlich (age 55) |
|---|---|
| Chief Financial Officer | Andrew Albert Kucharchuk (age 44) |
From Cero Therapeutics Holdings, Inc.'s Latest SEC 10-K Filing (filed 2026-04-15)
Key Strengths & Strategy (as disclosed to the SEC)
- Our proprietary approach to T cell engineering, which enables us to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy.
- Unlike currently approved chimeric antigen receptor ("CAR-T") therapies which have largely been active in hematological B cell malignancies, we believe CER-1236 will be active in both hematological malignancies and solid tumors.   On November 14, 2024, we received notice from the FDA that the Investigational New Drug Application ("IND") was cleared after being put on a brief clinical hold due to insufficient nonclinical data to adequately judge off target toxicity.
- Nevertheless, despite such limitations, sales of CAR-T cell therapies are anticipated to grow rapidly over the next several years and are expected to exceed $10 billion globally by 2030.   We believe that the preferential attributes engineered into our CER-T cell therapy enable us to overcome many of the limitations which hinder the wider application of CAR-T technology.
- Accordingly, we have developed CER-T cell manufacturing processes that closely resemble those used to produce existing engineered CAR-T cells.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| BDRX | Biodexa Pharmaceuticals plc | USD 3.1 | ▼ 7.74% |
| TVGN | Tevogen Bio Holdings Inc. | USD 10.75 | ▲ 2.67% |
| LRHC | La Rosa Holdings Corp. | USD 1.05 | ▲ 0% |
| TNON | Tenon Medical, Inc. | USD 0.62 | ▲ 2.12% |
| FOXO | FOXO Technologies Inc. | USD 0 | ▲ 0% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 02:30 UTC. This page is informational and not investment advice.